SLC2A3 and central nervous system cancer: Quantitative analysis showed no significant differences in GLUT3 expression among grade I-III gliomas, but a notable upregulation was observed in grade IV gliomas compared to lower grades (Fig. 1F), corroborating our prior analyses of GEO and CGGA database (Fig. 1A–E) and solidifying GLUT3’s status as a malignancy-progressive biomarker.